215 related articles for article (PubMed ID: 37971985)
1. Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.
Olsen A; Beall RF; Knox RP; Tu SS; Kesselheim AS; Feldman WB
PLoS Med; 2023 Nov; 20(11):e1004309. PubMed ID: 37971985
[TBL] [Abstract][Full Text] [Related]
2. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
Alhiary R; Kesselheim AS; Gabriele S; Beall RF; Tu SS; Feldman WB
JAMA; 2023 Aug; 330(7):650-657. PubMed ID: 37505513
[TBL] [Abstract][Full Text] [Related]
3. Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986-2020.
Feldman WB; Bloomfield D; Beall RF; Kesselheim AS
Health Aff (Millwood); 2022 Jun; 41(6):787-796. PubMed ID: 35579925
[TBL] [Abstract][Full Text] [Related]
4. Patenting Strategies on Inhaler Delivery Devices.
Demkowicz BJ; Tu SS; Kesselheim AS; Carrier MA; Feldman WB
Chest; 2023 Aug; 164(2):450-460. PubMed ID: 36842533
[TBL] [Abstract][Full Text] [Related]
5. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
Horrow C; Gabriele SME; Tu SS; Sarpatwari A; Kesselheim AS
JAMA Intern Med; 2024 Jul; 184(7):810-817. PubMed ID: 38739386
[TBL] [Abstract][Full Text] [Related]
6. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
[TBL] [Abstract][Full Text] [Related]
7. Characteristics Of Key Patents Covering Recent FDA-Approved Drugs.
Van de Wiele VL; Torrance AW; Kesselheim AS
Health Aff (Millwood); 2022 Aug; 41(8):1117-1124. PubMed ID: 35914209
[TBL] [Abstract][Full Text] [Related]
8. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
[TBL] [Abstract][Full Text] [Related]
9. Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS; Sinha MS; Avorn J
JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
[TBL] [Abstract][Full Text] [Related]
10. Patent Challenges And Litigation On Inhalers For Asthma And COPD.
Reddy S; Beall RF; Tu SS; Kesselheim AS; Feldman WB
Health Aff (Millwood); 2023 Mar; 42(3):398-406. PubMed ID: 36877911
[TBL] [Abstract][Full Text] [Related]
11. Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?
Beall RF; Nickerson JW; Kaplan WA; Attaran A
PLoS One; 2016; 11(2):e0148939. PubMed ID: 26910128
[TBL] [Abstract][Full Text] [Related]
12. A Method for Approximating Future Entry of Generic Drugs.
Beall RF; Darrow JJ; Kesselheim AS
Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
[TBL] [Abstract][Full Text] [Related]
13. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations.
Knoben JE; Scott GR; Tonelli RJ
Am J Hosp Pharm; 1990 Dec; 47(12):2696-700. PubMed ID: 2278285
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
15. Regulating Generic Ophthalmologic Drug Bioequivalence-Envisioning Accessibility for Patients.
Luke MC; Kozak D
J Ocul Pharmacol Ther; 2021 Apr; 37(3):157-161. PubMed ID: 33332225
[TBL] [Abstract][Full Text] [Related]
16. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
17. The global intellectual property ecosystem for insulin and its public health implications: an observational study.
Kaplan WA; Beall RF
J Pharm Policy Pract; 2017; 10():3. PubMed ID: 27446593
[TBL] [Abstract][Full Text] [Related]
18. Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.
Gupta R; Morten CJ; Zhu AY; Ramachandran R; Shah ND; Ross JS
JAMA Health Forum; 2022 May; 3(5):e221096. PubMed ID: 35977259
[TBL] [Abstract][Full Text] [Related]
19. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
20. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
Gupta R; Dhruva SS; Fox ER; Ross JS
J Manag Care Spec Pharm; 2017 Oct; 23(10):1066-1076. PubMed ID: 28944731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
